Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Adma Biologics Inc. (ADMA:NASDAQ), powered by AI.
Adma Biologics Inc. is currently trading at $8.71. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Adma Biologics Inc. on Alpha Lenz.
Adma Biologics Inc.'s P/E ratio is 14.1.
“Adma Biologics Inc. trades at a P/E of 14.1 (undervalued) with strong ROE of 35.6%. 3Y revenue CAGR of 49.0% highlights clear growth momentum.”
Ask for details →Adma Biologics Inc. is a biotechnology company that focuses on the development, manufacture, and commercialization of specialty plasma-derived biologics for the treatment and prevention of infectious diseases. At the core of its operations is the processing of human plasma to produce immunoglobulin products aimed at addressing immune deficiencies and other complex health conditions. The company's prominent products include Bivigam, an intravenous immunoglobulin used for the treatment of primary humoral immunodeficiency, and Asceniv, another intravenous immunoglobulin specifically tailored with hyperimmune antibodies. Adma Biologics serves critical roles within the healthcare sector, particularly in treating patients with immune system disorders, thus supporting a niche yet vital component of the pharmaceutical supply chain. Their products are crucial in meeting the demands of patients who require regular immune system support, distilling unique proteins and antibodies from donated plasma to help bolster patient health. With headquarters in Ramsey, New Jersey, and Boca Raton, Florida, the company plays a significant role in the advancements of plasma-derived therapeutics, catering to both domestic and international needs.
“Adma Biologics Inc. trades at a P/E of 14.1 (undervalued) with strong ROE of 35.6%. 3Y revenue CAGR of 49.0% highlights clear growth momentum.”
Ask for details →Adma Biologics Inc. (ticker: ADMA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 685 employees. Market cap is $2.1B.
The current price is $8.705 with a P/E ratio of 14.12x and P/B of 4.35x.
ROE is 35.56% and operating margin is 37.53%. Annual revenue is $510M.